Figure 1

HOXB13 target genes stratify primary from metastatic prostate tumors. (a) Venn Diagram of overlaps between DEGS (536 genes) in proximity of the Tumor specific AR binding sites (T-ARBS sites) and DEGS obtained following HOXB13 reduction (2677genes) in HOXB13pKO (n = 2 biological replicates) compared to C4-2B-Parental. (b) Heat map comparing expression of the 87 HOXB13 target genes obtained by integrative analysis in (a). Expression values were standardized to mean = 0 and standard deviation = 1 and hierarchically clustered. (c) Heat map of microarray analysis showing expression of 9 selected genes (HOTPAM9) in total n = 223 (194 primary and 29 metastatic tumors) in the Moffitt Cancer Center TCC data set. Red bars indicate metastatic tumors. (d) Principle Component Analysis (PCA) modeling HOXB13 target genes in 223 PC samples. (e) Heat map of prostate tumor microarray analysis showing expression of HOTPAM9 genes in the MSKCC data set (GSE21034). Red bars indicate metastatic tumors. (f) PCA analysis modeling HOTPAM9 in 179 samples (29 normal, 131 prostate adenocarcinomas and 19 metastasis). (g-i) Gene set enrichment analysis of HOXB13 target genes in castrated NKX3.1^haplo(N), NKX3.1^haplo PTEN^cnull (NP), and NKX3.1^haplo PTEN^cnull p53^cnull (NPp53) genetically engineered mouse models of prostate adenocarcinoma.